New trends in molecular and cellular biomarker discovery for colorectal cancer
New trends in molecular and cellular biomarker discovery for colorectal cancer
复制标题
DOI：
10.3748/wjg.v22.i25.5678
复制
发表时间：
2016-07-07
影响因子：
4.3
通讯作者：
Radpour, Ramin
中科院分区：
文献类型：
--
作者：
Aghagolzadeh, Parisa;Radpour, Ramin
结直肠癌（CRC）是全球癌症死亡的第三大原因，是多种遗传和表观遗传事件的多步骤肿瘤发生的结果。由于CRC在发展到晚期之前大多是无症状的，因此使用有效的筛查方法进行早期发现，选择适当的治疗策略和有效的随访计划对于降低CRC死亡率至关重要。基于个体化基因型和临床信息发现结直肠癌的生物标志物，有助于对特定类型和阶段的癌症患者进行分类，从而制定预防和治疗方案。这些与癌症相关的生物标志物应在广泛的标本（包括肿瘤组织、患者液体或粪便）中具有高度敏感性和特异性。可靠的生物标志物能够早期发现结直肠癌，提高早期诊断、预后、治疗反应预测和复发风险。我们对结直肠癌自然历史的理解的进步导致了不同结直肠癌相关分子和细胞生物标志物的发展。本文综述了结直肠癌生物标志物发现的新趋势和新方法，为结直肠癌的早期诊断、新治疗方法的开发和患者的随访提供了潜在的应用前景。
Colorectal cancer (CRC) is the third leading cause of cancer death worldwide, which is consequence of multistep tumorigenesis of several genetic and epigenetic events. Since CRC is mostly asymptomatic until it progresses to advanced stages, the early detection using effective screening approaches, selection of appropriate therapeutic strategies and efficient follow-up programs are essential to reduce CRC mortalities. Biomarker discovery for CRC based on the personalized genotype and clinical information could facilitate the classification of patients with certain types and stages of cancer to tailor preventive and therapeutic approaches. These cancer-related biomarkers should be highly sensitive and specific in a wide range of specimen(s) (including tumor tissues, patients' fluids or stool). Reliable biomarkers which enable the early detection of CRC, can improve early diagnosis, prognosis, treatment response prediction, and recurrence risk. Advances in our understanding of the natural history of CRC have led to the development of different CRC associated molecular and cellular biomarkers. This review highlights the new trends and approaches in CRC biomarker discovery, which could be potentially used for early diagnosis, development of new therapeutic approaches and follow-up of patients.